Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to cut breathing risks during sedation in seniors

NCT ID NCT07376577

Symptom relief Sponsor: The First Affiliated Hospital of Xinxiang Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a new drug combination (anricofen plus ciprofol) can provide safer deep sedation for elderly patients undergoing ERCP, a procedure to treat bile duct problems. The goal is to reduce breathing complications and speed up recovery compared to the standard sedative mix. About 141 patients aged 60-90 will take part, receiving one of two doses of the new combo or the standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anricofen and Ciprofol
What this could lead to
If successful, this could offer a safer sedation option for elderly patients undergoing ERCP, with fewer breathing problems and faster recovery.
What could go wrong
This is a small, early-stage trial with only 141 participants. The new drug combination may not prove safer or more effective than current methods, and unexpected side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 141 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Inclusion Criteria: 1. Age 60-90 years. 2. American Society of Anesthesiologists (ASA) physical status II or III. 3. Scheduled for elective endoscopic retrograde cholangiopancreatography (ERCP). 4. Body mass index (BMI) between 18 and 30 kg/m². 5. Willing and able to provide written informed consent. Exclusion Criteria: 1. Severe neurological disorders (acute stroke, uncontrolled seizures, epilepsy). 2. Psychiatric disorders or cognitive impairment (Mini-Mental State Examination score \<24). 3. Uncontrolled hypertension (preoperative blood pressure ≥180/110 mmHg) or hypotension (\<90/60 mmHg). 4. Severe cardiac disease: sinus bradycardia, sick sinus syndrome, unstable angina, or myocardial infarction within the past 3 months. 5. Severe hepatic or renal dysfunction. 6. Difficult airway or severe respiratory disease. 7. Achalasia. 8. Known allergy to anricofen, sufentanil, ciprofol, or other study medications. 9. Use of opioid analgesics or sedatives within 7 days prior to surgery. 10. Preoperative pulse oxygen saturation (SpO₂) \<90% on room air. 11. Pregnancy or lactation. 12. Participation in any other drug clinical trial within the past 3 months. 13. Refusal to participate in the study. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anesthesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

channelopathy-associated congenital insensitivity to pain, autosomal recessive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anesthesia Ciprofol ERCP Sedation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.